half life opposing force e10051 exe stopped working

Half life opposing force e10051 exe stopped working pro#

The method of claim 20, wherein a protease inhibitor comprises: amprenavir, tipranavir, indinavir, saquinavir mesylate, lopinavir and ritonavir (LPV/RTV), Fosamprenavir Calcium (FOS-APV), ritonavir, darunavir, atazanavir sulfate, nelfinavir mesylate or combinations thereof.Ģ4. The method of claim 20, wherein the NRTI comprises lamivudine, zidovudine, emtricitabine, abacavir, zalcitabine, dideoxycytidine, azidothymidine, tenofovir disoproxil fumarate, didanosine (ddI EC), dideoxyinosine, stavudine, abacavir sulfate or combinations thereof.Ģ3. The method of claim 20, wherein the NNRTI comprises: etravirine, efavirenz, nevirapine, rilpivirine, delavirdine, or nevirapine.Ģ2. The method of claim 1, optionally comprising a therapeutically effective amount of a non-nucleoside reverse transcriptase inhibitor (NNRTI), and/or a nucleoside reverse transcriptase inhibitor (NRTI) and/or a protease inhibitor.Ģ1. The method of claim 1, wherein a gRNA comprises at least one nucleic acid sequence set forth in Tables 1-5 or combinations of gRNAs.Ģ0. The method of claim 16, wherein accessory proteins comprise Nef, Vpr, Vpu, Vif or combinations thereof.ġ9. The method of claim 16, wherein regulatory proteins comprise: Tat, Rev or combinations thereof.ġ8. The method of claim 14, wherein the sequences encoding non-structural proteins comprise nucleic acid sequences encoding: regulatory proteins, accessory proteins or combinations thereof.ġ7.

Half life opposing force e10051 exe stopped working pro#

The method of claim 14, wherein the sequences encoding structural proteins comprise nucleic acid sequences encoding: Gag, Gag-Pol precursor, Pro (protease), Reverse Transcriptase (RT), integrase (In), Env or combinations thereof.ġ6. The method of claim 13, wherein the target sequences comprise one or more nucleic acid sequences in HIV comprising: long terminal repeat (LTR) nucleic acid sequences, nucleic acid sequences encoding structural proteins, non-structural proteins or combinations thereof.ġ5. The method of claim 8, wherein the retrovirus is a human immunodeficiency virus (HIV).ġ4. The method of claim of claim 11, wherein the expression vector comprises a lentiviral vector, an adenoviral vector, or an adeno-associated virus vector.ġ3. The method of claim 8, wherein the isolated nucleic acid is included in at least one expression vector.ġ2. The method of claim 8, wherein the at least one gRNA includes at least a first gRNA that is complementary to a target sequence in the integrated retroviral DNA and a second gRNA that is complementary to another target sequence in the integrated retroviral DNA, whereby the intervening sequences between the two gRNAs are removed.ġ1.

The method of claim 8, wherein the CRISPR/Cas fusion protein comprises catalytically deficient Cas protein (dCas), orthologs, homologs, mutants variants or fragments thereof.ġ0. The method of claim 1, wherein the at least one gene editing agent comprises: an isolated nucleic acid sequence encoding a Clustered Regularly Interspaced Short Palindromic Repeat (CRISPR)-associated endonuclease/Cas (CRISPR/Cas) and at least one guide RNA (gRNA), the gRNA being complementary to a target nucleic acid sequence in a retroviral genome.ĩ. The method of claim 1, wherein the at least one antiretroviral agent and at least one gene-editing agent are administered sequentially.Ĩ. The method of claim 1, wherein the at least one antiretroviral agent and at least one gene-editing agent are co-administered.ħ. The method of claim 1, wherein the at least one antiretroviral agent is administered to the subject prior to administering the at least one gene editing agent.Ħ. The method of claim 3, wherein the at least one antiretroviral agent comprises: myristolyated dolutegravir, lamivudine, abacavir, rilpivirine or combinations thereof.ĥ. The method of claim 2, wherein the at least one antiretroviral agent is nanoformulated.Ĥ. The method of claim 1, wherein the antiretroviral agent is formulated as a long-acting slow effective release (LASER) antiretroviral agent.ģ. A method of eradicating or eliminating a retrovirus in a subject, comprising administering to a patient a composition comprising a therapeutically effective amount of at least one antiretroviral agent and/or a composition comprising a therapeutically effective amount of at least one gene editing agent, thereby eradicating or eliminating the retrovirus in a subject.Ģ.